NEW YORK (GenomeWeb News) – Crown Bioscience and Horizon Discovery today announced that they will partner on offering new in vivo X-MAN models as a service to Crown's customers.
Horizon's X-MAN cell lines are used for in vivo and in vitro drug discovery model validation. The Cambridge, UK-baed firm already offers more than 450 X-MAN cell lines, as well as more than 50 phenotypic cell-based assays, and its SyntheTx drug/RNAi screening platform.
"The novel in vivo models we are developing based on the X-MAN cell lines offer new opportunities for clients to collaborate with us at an early stage and validate the models based on their needs," Jean-Pierre Wery, president of Santa Clara, Calif.-based Crown Bioscience said in a statement. "This will allow greater insights and better means to evaluate the therapeutic efficacy of compounds and their impact on key physiological functions."
Financial and other terms of the alliance were not disclosed.